All Semaglutide certificates

Semaglutide 10 mg Certificate of Analysis Batch APL-SEMA10-2608-01

Semaglutide 10 mg from batch APL-SEMA10-2608-01 was analysed on 31 August 2026 and measured 98.86% purity by HPLC / Mass Spectrometry, passing all 5 release tests.

Purity
98.86%
Result
All 5 tests passed
Tested
31 August 2026
Method
HPLC / Mass Spectrometry
Net content
10.09 mg

Independent verification

Semaglutide 10 mg is independently verified by Ozcanium Analytics, an independent Australian laboratory, at 98.89% purity by UPLC-MS/MS, analysed 7 September 2026 on lot APL-SEMA10-2609-01, net content 9.75 mg, verification code OZ-HPLCMS-TP98; bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL, analysed 8 September 2026, verification code OZ-ENDOTX-TEP2.

Issued by Ozcanium Analytics. Covers every vial size of this compound; each report opens as the laboratory issued it.

Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.

The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 1 of 2

Certificate of Analysis Semaglutide 10 mg Batch APL-SEMA10-2608-01
Compound
Semaglutide
Lot Number
APL-SEMA10-2608-01
Analysis Date
31 August 2026
Method
HPLC / Mass Spectrometry
Purity
98.86%
Net Content
10.09 mg
Semaglutide vial
CAS Number
910463-68-2
Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Form
Lyophilised Powder
Manufactured
August 2026
Issued
1 September 2026
Document ID
APL-COA-SEMA10-2608-01
Verification Code
Batch traceable
SequenceHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-gamma-Glu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

High Performance Liquid Chromatography (HPLC-UV) Chromatogram

mAUPDA 214 nm025050075010003.544.555.566.577.5 min 4.1104.3804.620Semaglutide5.0406.710

Main peak integrated at 98.86% of total area; no single impurity peak exceeds 0.47%.

Peak List

Peaks detected: 5
#Time (min)Area% AreaIdentification
14.11022,3200.310—
24.38033,8400.470—
34.6207,117,92098.860Semaglutide
45.04018,7200.260—
56.7107,2000.100—

Analytical Results

TestSpecificationResultStatus
AppearanceWhite/Off-White Lyophilised PowderConformsPASS
Identity (MS)ConfirmedConfirmedPASS
Purity (HPLC)≥98.0%98.86%PASS
Peptide Content95–105%98.4%PASS
Endotoxins<0.5 EU/mg<0.20 EU/mgPASS

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 2 of 2

Semaglutide 10 mg

CAS Number: 910463-68-2

Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis

Identity confirmation with SIM

Analysis date: 31 August 2026
Monitored (m/z)Detected (m/z)Relative Intensity
824823.751.3
10291029.432.05
13721372.241.15

Detection assignment: Semaglutide

Collected Mass Spectrum

Intensity ×107

00.511.522.55007009001100130015001700 m/z 82410291372

Verification Protocol

  • Identity confirmed by mass spectrometry against the expected ion channels.
  • Purity measured by HPLC as peak area against all integrated impurity peaks.
  • Batch traceability: this document reports the lot number printed on the vial.
  • Analysis performed in-house by Australian Peptide Labs.

Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.

View Semaglutide in the catalogueHow to read this certificate